Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TPMT | P51580 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7767271 | 0.80 | NPSR1 (0.46) | TSHRKMT2AMEN1POLBNPC1 | |
| SCHEMBL9438559 | 0.79 | TPMT (0.41) | TSHRTP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL19663875 | 0.78 | NPC1 (0.55) | TSHRTP53KMT2AMEN1POLB | |
| SCHEMBL976776 | 0.78 | TSHR (0.55) | TSHRTP53KMT2AMEN1POLB | |
| SCHEMBL10865352 | 0.78 | ALDH1A1 (0.45) | TSHRKMT2AMEN1POLBNPC1 | |
| SCHEMBL27458679 | 0.77 | CA12 (0.46) | TSHRTP53KMT2AMEN1POLB | |
| SCHEMBL8953838 | 0.77 | POLB (0.53) | TSHRTP53KMT2AMEN1POLB | |
| SCHEMBL11517667 | 0.75 | TSHR (0.50) | TSHRTP53KMT2AMEN1POLB | |
| SCHEMBL3911047 | 0.75 | TSHR (0.52) | TSHRTP53KMT2AMEN1POLB | |
| Terephthalic Acid SCHEMBL2187152 | 0.75 | TSHR (0.63) | TSHRTP53KMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293660-A1 | CHEMICALLY-DEFINED NON-POLYMERIC VALENCY PLATFORM MOLECULES AND CONJUGATES THEREOF | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2008-11-27 | — | — | US | disclosed |
| US-7351855-B2 | Chemically defined non-polymeric valency platform molecules and conjugates thereof | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070254851-A1 | Chemically-defined non-polymeric valency platform molecules and conjugates thereof | LA JOLLA PHARMACEUTICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| EP-1808183-A2 | Chemically-defined non-polymeric valency platform molecules and conjugates thereof | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2007-07-18 | — | — | EP | disclosed |
| CN-1318023-C | Chemically-defined non-polymeric valency platform molecules and conjugates thereof | JOLLA PHARMACEUT CO (US) | 2007-05-30 | — | — | CN | disclosed |
| US-7208156-B2 | Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2007-04-24 | — | — | US | disclosed |
| US-7163683-B2 | Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
| US-7138244-B2 | Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| US-7115581-B2 | Chemically-defined non-polymeric valency platform molecules and conjugates thereof | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2006-10-03 | — | — | US | disclosed |
| US-20050170436-A1 | Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule | LA JOLLA PHARMACEUTICAL COMPANY | 2005-08-04 | — | — | US | disclosed |
| US-5552391-A | Chemically-defined non-polymeric valency platform molecules and conjugates thereof | LA JOLLA PHARMACEUTICAL COMPANY (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0722318-A1 | CHEMICALLY-DEFINED NON-POLYMERIC VALENCY PLATFORM MOLECULES AND CONJUGATES THEREOF | LA JOLLA PHARMACEUTICAL (US) | 1996-07-24 | — | — | EP | disclosed |
| WO-1995007073-A1 | CHEMICALLY-DEFINED NON-POLYMERIC VALENCY PLATFORM MOLECULES AND CONJUGATES THEREOF | LA JOLLA PHARMACEUTICAL COMPANY (US) | 1995-03-16 | — | — | WO | disclosed |
| EP-0642798-A2 | Chemically-defined non-polymeric valency platform molecules and conjugates thereof | LA JOLLA PHARMACEUTICAL COMPANY (CA) | 1995-03-15 | — | — | EP | disclosed |
| EP-0624377-A2 | Lysosomal enzyme-cleavable antitumor drug conjugates | Bristol-Myers Squibb Company (US) | 1994-11-17 | — | — | EP | disclosed |
| EP-0504321-A4 | ENHANCED CAPTURE OF TARGET NUCLEIC ACID BY THE USE OF OLIGONUCLEOTIDES COVALENTLY ATTACHED TO POLYMERS | — | 1993-07-14 | — | — | EP | disclosed |
| EP-0504321-A1 | ENHANCED CAPTURE OF TARGET NUCLEIC ACID BY THE USE OF OLIGONUCLEOTIDES COVALENTLY ATTACHED TO POLYMERS. | MICROPROBE CORP (US) | 1992-09-23 | — | — | EP | disclosed |
| WO-1991008307-A1 | ENHANCED CAPTURE OF TARGET NUCLEIC ACID BY THE USE OF OLIGONUCLEOTIDES COVALENTLY ATTACHED TO POLYMERS | MICROPROBE CORPORATION (US) | 1991-06-13 | — | — | WO | disclosed |
| WO-1990001564-A1 | METHODS FOR MULTIPLE TARGET ANALYSES THROUGH NUCLEIC ACID HYBRIDIZATION | MICROPROBE CORPORATION (US) | 1990-02-22 | — | — | WO | disclosed |
| WO-1989006701-A1 | THIOL-REACTIVE OLIGONUCLEOTIDE INTERMEDIATES AND PROCESSES FOR CONJUGATION OF OLIGONUCLEOTIDES WITH ENZYMES | MICROPROBE CORPORATION (US) | 1989-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293660-A1 | CHEMICALLY-DEFINED NON-POLYMERIC VALENCY PLATFORM MOLECULES AND CONJUGATES THEREOF | SSB, PCNA, NCL | TSHR 2076/4885TP53 294/4885KMT2A 680/4885 |
| US-20050170436-A1 | Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule | CD4, CD74, LY96 | TSHR 2251/4885TP53 162/4885KMT2A 2466/4885 |
| US-20070254851-A1 | Chemically-defined non-polymeric valency platform molecules and conjugates thereof | SSB, PCNA, NCL | TSHR 2076/4885TP53 294/4885KMT2A 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.